Cancer Research UK and Medidata Partner to Streamline Data Collection and Management for Cancer Clinical Trials


Applied Clinical Trials

NEW YORK, N.Y. – March 25, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and Cancer Research UK, the world’s largest charitable funder of cancer research, today announced that the Medidata Clinical Cloud® has been selected to support the charity’s ground-breaking drug discovery research.

In collaboration with academic and industry partners, Cancer Research UK’s Centre for Drug Development (CDD) translates exciting new discoveries made in the lab into cutting-edge new cancer treatments for patients. To further this work, the CDD is leveraging Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) to conduct faster, safer clinical trials at institutes, universities and hospitals across the UK.

“Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress across all our trials,” said Dr. Nigel Blackburn, director of Cancer Research UK’s CDD. “Having immediate access to high-quality data will ultimately help us shorten trial delivery times, reduce costs and maximise the output of studies so that we can accelerate progress and bring new treatments to cancer patients sooner.”

He added: “Transitioning to Medidata’s software-as-a-service platform for clinical trial management and execution-and partnering with a technology company that really understands our mission and R&D needs-will further increase collaboration between our research partners, especially those in the academic space.”

Using Medidata’s cloud-based data management and capture system, the CDD will make clinical data from its future trials easily accessible to researchers in real time, streamlining the process of setting up and running cancer trials. By providing a standardised, central system for data entry, the Medidata platform will improve data quality, allow clinicians to easily monitor patients’ safety and enable more insightful decision making across all CDD trials.

“Cancer Research UK is recognized internationally for its vital leadership in helping to increase cancer survival rates, and Medidata is thrilled to be part of its journey,” said Glen de Vries, Medidata’s president. “We share Cancer Research UK’s quest for improved patient outcomes and are committed to providing technology that helps fuel innovation to uncover new approaches to cancer diagnosis, treatment and prevention.” 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.